Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
Company: Jazz Pharmaceuticals Plc (Ireland)
Filing Date: July 10, 2012
Reporting Period: Current report for events occurring on July 10, 2012
Primary Product: Xyrem (sodium oxybate) oral solution
Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory event. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material event reported is the submission of a Citizen Petition to the U.S. Food and Drug Administration (FDA) by Jazz Pharmaceuticals, Inc. (a wholly owned subsidiary). The petition addresses the requirements for Abbreviated New Drug Applications (ANDA) referencing Xyrem, specifically targeting an application filed by Roxane Laboratories, Inc. (Roxane).
Guidance, Outlook, and Risks
- Regulatory Action: The Company requested the FDA to rescind acceptance of any previously accepted ANDA referencing Xyrem that lacked a proposed risk management system at the time of acceptance, specifically citing Roxane's application.
- Future Submissions: The petition asks the FDA not to accept future ANDAs for Xyrem without a sufficient proposed risk management system at the time of submission.
- Patent Stay Request: The Company requested that if a sponsor (including Roxane) later submits a complete risk management system, the FDA should not approve the ANDA for up to thirty months from the date of Paragraph IV certification notice, allowing time for patent litigation.
- Rationale: The Company believes Roxane's ANDA, submitted in July 2010, lacked a risk management system until at least October 2011. The Company argues the FDA's premature acceptance of Roxane's ANDA caused the thirty-month Hatch-Waxman stay and related litigation to begin prematurely.
- Outlook and Uncertainty: The Company states it cannot predict when or if the FDA will respond to the petition or the effect of any such action on ongoing litigation with Roxane.
Key Facts for Investor Verification
- Verify the status of the ongoing patent litigation between Jazz Pharmaceuticals and Roxane Laboratories regarding Xyrem.
- Monitor FDA responses to the Citizen Petition filed on July 10, 2012, regarding the acceptance of ANDAs without risk management systems.
- Assess the potential impact of a thirty-month stay on generic competition for Xyrem if the FDA grants the Company's request.
- Review the timeline of Roxane's submissions regarding their risk management system as disclosed in the filing.